Cabazitaxel Plus Lapatinib as Therapy for HER2-Positive Metastatic Breast Cancer Patients With Intracranial Metastases
Status:
Terminated
Trial end date:
2017-04-01
Target enrollment:
Participant gender:
Summary
This phase II trial will combine two agents, cabazitaxel and lapatinib, to treat patients
with metastatic breast cancer (MBC) which has metastasized to the brain. The first portion of
the study will determine the optimal dose of the cabazitaxel/lapatinib combination to
administer to patients. After determining the optimal dose, patients will continue treatment
with cabazitaxel and lapatinib to assess response to treatment with these agents.